"My argument to Mehmet Oz is that if you want to protect Medicare costs in 10 years, have [the Affordable Care Act] and Medicare plans list these drugs now," Ricks said to Bloomberg. "We know so much about how much cost savings there will be downstream in heart disease and other conditions." This statement emphasizes the potential long-term benefits of covering GLP-1 drugs for managing obesity, highlighting a proactive approach to healthcare costs.